✦ LIBER ✦

Benefit–risk outcomes with adalimumab versus methotrexate for moderate to severe psoriasis during the first year of treatment

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of benefit–risk profiles for

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Comparison of benefit–risk profiles with

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Adalimumab treatment for moderate psoria

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Risk-benefit analysis of adalimumab vers

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Benefit-risk analysis of adalimumab vers

✍ Kristian Reich; James Signorovitch; Karthik Ramakrishnan; Andrew P. Yu; Eric Q. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 407 KB

The benefits of adalimumab on clinical a

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB